CorMedix Inc. Q2 2026 Earnings Call Summary
CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 profitability (EBITDA guidance), near-term operational spend, and the probability-weighted path to REZZAYO prophylaxis NDA submission and subsequent FDA action.
Market read
The call provides a quantified EBITDA guidance raise and a concrete regulatory timeline for REZZAYO prophylaxis, both of which can drive near-term positioning and options pricing into 2H 2026.
What to watch
The guidance excludes potential Medicare Advantage contributions due to timing uncertainty, and REZZAYO label scope is still subject to FDA review after the Q3 2026 sNDA.
Background
The article summarizes CorMedix’s Q2 2026 earnings call, focusing on DefenCath commercialization post-TDAPA reimbursement transition and REZZAYO prophylaxis pipeline execution.
Ticker impact
CorMedix raised full-year 2026 adjusted EBITDA guidance to $125-$140M and reiterated REZZAYO sNDA timing for prophylaxis in Q3 2026.
Likely positive bias for shares into the Q3 2026 sNDA window, with volatility around Medicare Advantage and ESRD rule updates.
The article provides specific, time-bound catalysts (sNDA submission, potential FDA action window, REZZAYO scale-up staffing) and a quantified EBITDA guidance range, which can drive re-rating versus prior expectations.
Market effects
Dialysis and antifungal specialty pharma names may see read-through from DefenCath reimbursement transition management and REZZAYO prophylaxis progress.
Primarily US reimbursement and FDA-timeline driven, with limited direct regional spillover.
Mundipharma-to-CorMedix NDA ownership transfer contingent on FDA approval links US regulatory outcomes to broader commercialization planning.
Counterpoint
Key revenue visibility depends on Medicare Advantage contracting progress and LDO pilot adoption, both explicitly not quantified for 2027 yet.
Key entities
- public_companyCorMedix Inc.
US-listed specialty pharma company discussed throughout the earnings call summary, including DefenCath and REZZAYO milestones and 2026 guidance.
- product_pipelineREZZAYO
Pipeline antifungal prophylaxis program with positive Phase III ReSPECT data and planned Q3 2026 sNDA submission.
- productDefenCath
Dialysis-related therapy whose utilization is described as stable through the initial post-TDAPA reimbursement transition.
- regulatory_reimbursementTDAPA
Reimbursement expiration referenced as driving expected attrition among smaller dialysis providers.
- regulatoryESRD rule
Final ESRD rule expected in November 2026 that may change commercial strategy under finalized Medicare reimbursement.
